Joel S. Parker

123.6k total citations · 12 hit papers
278 papers, 29.7k citations indexed

About

Joel S. Parker is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Joel S. Parker has authored 278 papers receiving a total of 29.7k indexed citations (citations by other indexed papers that have themselves been cited), including 154 papers in Molecular Biology, 118 papers in Cancer Research and 93 papers in Oncology. Recurrent topics in Joel S. Parker's work include Cancer Genomics and Diagnostics (52 papers), Breast Cancer Treatment Studies (39 papers) and Gene expression and cancer classification (38 papers). Joel S. Parker is often cited by papers focused on Cancer Genomics and Diagnostics (52 papers), Breast Cancer Treatment Studies (39 papers) and Gene expression and cancer classification (38 papers). Joel S. Parker collaborates with scholars based in United States, Spain and Canada. Joel S. Parker's co-authors include Charles M. Perou, Xiaping He, Aleix Prat, Andrew B. Nobel, J. S. Marron, Philip S. Bernard, Matthew J. Ellis, Torsten O. Nielsen, Maggie C.U. Cheang and Samuel Leung and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Joel S. Parker

266 papers receiving 29.2k citations

Hit Papers

Repeated observation of b... 2003 2026 2010 2018 2003 2009 2009 2010 2006 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Repeated observation of breast tumor subtypes in independent gene expression data sets
    2003 4.0k citations Joel S. Parker, J. S. Marron et al. profile →
  2. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
    2009 3.1k citations Joel S. Parker, Michael E. Mullins et al. Journal of Clinical Oncology profile →
  3. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
    2009 1.6k citations Maggie C.U. Cheang, Stephen Chia et al. JNCI Journal of the National Cancer Institute profile →
  4. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
    2010 1.6k citations Aleix Prat, Joel S. Parker et al. profile →
  5. Extensive post-transcriptional regulation of microRNAs and its implications for cancer
    2006 691 citations Joel S. Parker et al. profile →
  6. A custom microarray platform for analysis of microRNA gene expression
    2004 644 citations Joel S. Parker, Charles M. Perou et al. profile →
  7. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
    2014 613 citations Katherine A. Hoadley, Joel S. Parker et al. profile →
  8. RNA polymerase is poised for activation across the genome
    2007 596 citations Joel S. Parker et al. profile →
  9. A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer
    2010 542 citations Torsten O. Nielsen, Joel S. Parker et al. Clinical Cancer Research profile →
  10. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression
    2004 500 citations Christine H. Chung, Joel S. Parker et al. profile →
  11. Increased Epidermal Growth Factor Receptor Gene Copy Number Is Associated With Poor Prognosis in Head and Neck Squamous Cell Carcinomas
    2006 448 citations Christine H. Chung, Kim Ely et al. Journal of Clinical Oncology profile →
  12. Male breast cancer: a disease distinct from female breast cancer
    2018 230 citations Joel S. Parker, Sara R. Selitsky et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joel S. Parker United States 72 16.2k 13.2k 11.4k 4.3k 3.5k 278 29.7k
P. Andrew Futreal United States 71 16.9k 1.0× 9.3k 0.7× 7.8k 0.7× 4.9k 1.2× 4.1k 1.2× 291 28.0k
Christos Sotiriou Belgium 76 12.3k 0.8× 13.8k 1.0× 15.6k 1.4× 4.4k 1.0× 2.9k 0.8× 366 29.1k
Anne‐Lise Børresen‐Dale Norway 65 14.8k 0.9× 12.4k 0.9× 10.9k 0.9× 3.0k 0.7× 4.5k 1.3× 190 26.0k
Jonathan R. Pollack United States 57 14.9k 0.9× 9.1k 0.7× 8.6k 0.7× 3.9k 0.9× 4.8k 1.4× 123 25.9k
Carsten Denkert Germany 79 11.5k 0.7× 11.3k 0.9× 15.3k 1.3× 4.4k 1.0× 1.9k 0.6× 522 29.5k
Torsten O. Nielsen Canada 77 10.3k 0.6× 14.5k 1.1× 16.1k 1.4× 7.7k 1.8× 3.3k 0.9× 241 31.1k
John A. Foekens Netherlands 79 13.5k 0.8× 10.6k 0.8× 11.4k 1.0× 3.6k 0.8× 3.3k 0.9× 337 25.5k
Paul S. Meltzer United States 93 22.7k 1.4× 7.2k 0.5× 9.2k 0.8× 5.6k 1.3× 5.3k 1.5× 384 36.0k
Peter J. Campbell United Kingdom 77 17.9k 1.1× 9.7k 0.7× 5.6k 0.5× 2.8k 0.7× 4.0k 1.2× 251 31.8k
Xin‐Yuan Guan China 85 18.3k 1.1× 8.7k 0.7× 7.9k 0.7× 2.6k 0.6× 3.6k 1.0× 645 28.7k

Countries citing papers authored by Joel S. Parker

Since Specialization
Citations

This map shows the geographic impact of Joel S. Parker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel S. Parker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel S. Parker more than expected).

Fields of papers citing papers by Joel S. Parker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel S. Parker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel S. Parker. The network helps show where Joel S. Parker may publish in the future.

Co-authorship network of co-authors of Joel S. Parker

This figure shows the co-authorship network connecting the top 25 collaborators of Joel S. Parker. A scholar is included among the top collaborators of Joel S. Parker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel S. Parker. Joel S. Parker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rajagopal, Padma Sheila, Jeffrey Mueller, Galina Khramtsova, et al.. (2024). The VEGF-Hypoxia Signature Is Upregulated in Basal-like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer. Clinical Cancer Research. 30(11). 2609–2618. 7 indexed citations
2.
Marron, J. S., et al.. (2023). Translating transcriptomic findings from cancer model systems to humans through joint dimension reduction. Communications Biology. 6(1). 179–179. 4 indexed citations
3.
Routh, Eric D., Amanda E.D. Van Swearingen, Maria J. Sambade, et al.. (2022). Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419. Frontiers in Oncology. 12. 818693–818693. 6 indexed citations
4.
Bortone, Dante S., Mark G. Woodcock, Joel S. Parker, & Benjamin G. Vincent. (2020). Improved T-cell Receptor Diversity Estimates Associate with Survival and Response to Anti–PD-1 Therapy. Cancer Immunology Research. 9(1). 103–112. 13 indexed citations
5.
Smith, Christof C., Shengjie Chai, Samuel Lee, et al.. (2019). Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes. Cancer Immunology Research. 7(10). 1591–1604. 47 indexed citations
6.
Kensler, Kevin H., Venkat Sankar, Jun Wang, et al.. (2018). PAM50 Molecular Intrinsic Subtypes in the Nurses' Health Study Cohorts. Cancer Epidemiology Biomarkers & Prevention. 28(4). 798–806. 37 indexed citations
7.
Chason, Kelly D., Ilona Jaspers, Joel S. Parker, et al.. (2018). Age-Associated Changes in the Respiratory Epithelial Response to Influenza Infection. The Journals of Gerontology Series A. 73(12). 1643–1650. 19 indexed citations
8.
Prat, Aleix, Alejandro Navarro, Laia Paré, et al.. (2017). Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Research. 77(13). 3540–3550. 277 indexed citations
9.
Brooks, Samira A., Amir H. Khandani, Julia R. Fielding, et al.. (2016). Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression. Clinical Cancer Research. 22(12). 2950–2959. 19 indexed citations
10.
Tong, Frances, et al.. (2016). Immunophenotyping and Transcriptomic Outcomes in PDX-Derived TNBC Tissue. Molecular Cancer Research. 15(4). 429–438. 9 indexed citations
11.
Karginova, Olga, Marni B. Siegel, Amanda E.D. Van Swearingen, et al.. (2015). Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA -Mutated and BRCA –Wild-Type Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 14(4). 920–930. 53 indexed citations
12.
Iglesia, Michael D., Benjamin G. Vincent, Joel S. Parker, et al.. (2014). Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer. Clinical Cancer Research. 20(14). 3818–3829. 194 indexed citations
13.
Roll, J. Devon, Ashley G. Rivenbark, Rupninder Sandhu, et al.. (2013). Dysregulation of the epigenome in triple-negative breast cancers: Basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. Experimental and Molecular Pathology. 95(3). 276–287. 47 indexed citations
14.
Dunbier, Anita K., H Anderson, Zara Ghazoui, et al.. (2011). Association between breast cancer subtypes and response to neoadjuvant anastrozole. Steroids. 76(8). 736–740. 37 indexed citations
15.
Nielsen, Torsten O., Joel S. Parker, Samuel Leung, et al.. (2010). A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research. 16(21). 5222–5232. 542 indexed citations breakdown →
16.
Parker, Joel S., Michael E. Mullins, Maggie C.U. Cheang, et al.. (2009). Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. Journal of Clinical Oncology. 27(8). 1160–1167. 3093 indexed citations breakdown →
17.
Cheang, Maggie C.U., Stephen Chia, David Voduc, et al.. (2009). Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. JNCI Journal of the National Cancer Institute. 101(10). 736–750. 1641 indexed citations breakdown →
18.
Crowder, Robert J., Chanpheng Phommaly, Tao Yu, et al.. (2009). PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast Cancer. Cancer Research. 69(9). 3955–3962. 174 indexed citations
19.
Silva, José M., Krista Marran, Joel S. Parker, et al.. (2008). Profiling Essential Genes in Human Mammary Cells by Multiplex RNAi Screening. Science. 319(5863). 617–620. 225 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P. Andrew Futreal Breakdown of academic impact, for papers by Christos Sotiriou Breakdown of academic impact, for papers by Anne‐Lise Børresen‐Dale Breakdown of academic impact, for papers by Jonathan R. Pollack Breakdown of academic impact, for papers by Carsten Denkert Breakdown of academic impact, for papers by Torsten O. Nielsen Breakdown of academic impact, for papers by John A. Foekens Breakdown of academic impact, for papers by Paul S. Meltzer Breakdown of academic impact, for papers by Peter J. Campbell Breakdown of academic impact, for papers by Xin‐Yuan Guan
Rankless by CCL
2026